Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- No Plan for LLP Split-Off at This Point: Sumitomo Dainippon Chief
May 15, 2017
- Sumitomo Dainippon Scores Record Earnings on Latuda Boost
May 15, 2017
- Sales of 4 Japan Drug Majors Dip 3.7% on Stronger Yen, Price Cuts; Global Brands Solid
May 12, 2017
- Daiichi Sankyo Eclipses Takeda, Becomes Top Maker by Japan Ethical Drug Sales
May 12, 2017
- AZ Union Petitions Court to Adjudicate Labor Dispute, Claiming Unfair Demotions and Pay Cuts
May 12, 2017
- Mitsubishi Tanabe to Transfer Production of Medway to Outside Party
May 12, 2017
- Chugai Grants JW Pharmaceutical Marketing Rights for Emicizumab in South Korea
May 12, 2017
- Astellas, Univ. of Tokyo to Expand Research Collaboration on Rice-Based Oral Vaccine
May 12, 2017
- Baxalta Files Patent Infringement Lawsuit against Chugai over Development of Hemophilia A Treatment Emicizumab in US
May 12, 2017
- Mitsubishi Tanabe Eyes M&As for Post-Radicava Strategy in US: President
May 11, 2017
- There Could Be Discussions on Price Reviews for Add’l Indication-Driven Sales Growth: Weber
May 11, 2017
- Mitsubishi Tanabe Sees Bullish Simponi, but Sales Slightly Lower on Price Revision
May 11, 2017
- Shionogi Wants to Zero In on Innovative Drugs, Teshirogi says on LLP Transfer
May 11, 2017
- Shionogi Enjoys Rise in Japan Sales, Profits on HIV Royalty Revenue
May 11, 2017
- Eisai Plans Japan Filing for Lenvima’s HCC Indication in June: CEO
May 11, 2017
- Eisai’s Global Brands Brisk but Sales Slip on Forex, Drug Price Revision
May 11, 2017
- Takeda’s Japan Ethical Sales Sag 6.8% on LLP Transfer, but Underlining Revenue Grows
May 11, 2017
- Fujifilm Invests 170 Million Yen in Regenerative Medicine Startup
May 11, 2017
- Takeda, UK Bioventure GammaDelta Pair Up for Development of New Immunotherapies Based on T cells
May 11, 2017
- Sales Rep Survey - 2: Drug Makers Exploring New Values amid Shift to Community-Based Care
May 10, 2017
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…